09:59 AM EST - Sernova Corp. : Today presented interim positive results from its ongoing Phase 1/2 clinical trial investigating islet allotransplantation into pre-vascularized Sernova Cell Pouch™ during an oral presentation at the 2023 IPITA, IXA, and CTRMS Joint Congress in San Diego, California. Sernova Corp.
shares T.SVA are trading up $0.03 at $0.74.
